Skip to content

Author

G. Gandaglia

We have 8 of 119 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Development and External Validation of an Updated Nomogram Including Both MRI and Local PSMA PET/CT Information for the Prediction of Side-specific Extraprostatic Extension in Patients Treated with Radical Prostatectomy

Take Home Message A combined prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)–magnetic resonance imaging (MRI) model improved extraprostatic extension prediction in development but showed similar performance to MRI in external validation. The added value of PSMA PET/CT a...

V. Sweere, A. B. Bruins Slot, J. Heetman et al. · 0 citations
Review Open access Oct 2026

Prostate cancer worldwide: updated epidemiology, disparities, and screening implications.

Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity.

R. Bernardino, David-Dan Nguyen, Sigrid V. Carlsson et al. · 0 citations
Review Oct 2026

Epidemiology, Risk Factors, and Prevention of Prostate Cancer.

CONTEXT There are substantial regional differences in prostate cancer (PCa) epidemiology reflecting differences in risk factors, screening, management, and access to care. OBJECTIVE To assess geographical differences and temporal trends in PCa incidence and mortality and PCa risk factors. EVIDENCE ACQUISITION Estim...

G. Gandaglia, A. Weiner, A. Briganti et al. · 0 citations
Review Open access Sep 2026

PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review

Comprehensive data on PSMA expression dynamics are still needed before this approach can be implemented in routine clinical practice, but the potential to personalize treatment strategies depending on treatment response is held.

J. le Guevelou, M. Bauckneht, T. Soeterik et al. · 0 citations
Sep 2026

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with cryotherapy vs. external beam radiation therapy

Population-based observations indicate that cryotherapy is associated with a higher risk of CSM compared with EBRT in these patients, and univariable competing risks regression models tested for CSM differences after accounting for other-cause mortality (OCM) as a competing event.

L. Quarta, M. Petix, M. Filzmayer et al. · 0 citations
Open access Aug 2026

Focal Therapy for Prostate Cancer.

This retrospective study uses data from the National Cancer Database to examine patterns and temporal trends in use of focal therapy for prostate cancer in US cancer centers; characterize inappropriate use in low-, high-, or very–high-risk disease; and describe intermediate-risk use.

A. Cosenza, David-Dan Nguyen, Z. Qian et al. · 1 citation
Aug 2026

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

INTRODUCTION Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...

L. Quarta, M. Petix, M. Filzmayer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.